Paris, France
Research view
Myocarditis: who works on it
Groups that published on this disease or run trials on it, from public registries and publications. Researchers appear by name only once their profile is published.
Find fellow researchers
One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.
- All targets
- PD-1 0
- PD-L1 0
- IL-17 0
- JAK 0
- NRF2 0
- ABL1 0
- AR 0
- BRAF 0
- CD40 0
- CTLA-4 0
- FTO 0
- GLP-1 0
- HER2 0
- HMGB1 0
- IL-4 0
- JNK 0
- mTOR 0
- PDGFR 0
- PINK1 0
- PPAR 0
- SGLT2 0
- VEGF 0
- YAP 0
EU-13 is a filter, not a ranking: it only narrows the list.
Paris, France
Rochester, United States
Chinese Academy of Medical Sciences & Peking Union Medical College · Beijing, China
Team details appear once the team leader joins.
Is this your team? Claim it
Latest publication · Lancet Gastroenterol Hepatol, Nov 2025Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trial.
Berlin, Germany
Paris, France
Wuhan, China
Cambridge, United States
Berlin, Germany
Cleveland, United States
Paris, France
Berlin, Germany
Baltimore, United States
Padua, Italy
Beijing, China
Jacksonville, United States
Milan, Italy
Toronto, Canada
San Francisco, United States
King's College London · London, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
Latest publication · Int J Mol Sci, Dec 2025Fatal Myocarditis Following Adjuvant Immunotherapy: A Case Report and Literature Review.
Milan, Italy
Wuhan, China
Paris, France
Zurich, Switzerland
24 of 1,016 institutions, ordered by recent publications and open trials. This is not a ranking of quality.
Who stopped a trial, and why
Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.
Terminated
[68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation
“Recruitment difficulties”Registry text, quoted unchanged. Source
Terminated
“Low/slow accrual (change in standard treatment practice)”Registry text, quoted unchanged. Source
Terminated
Immunosuppressive Treatment in Chronic Virus-Negative Inflammatory Cardiomyopathy
“Premature end of recruitment due to lack of eligible patients. Within two years of recruitment only nine patients could be randomized out of 130 required patients as per trial protocol.”Registry text, quoted unchanged. Source
Terminated
“Study was stopped due to negative preliminary analysis, slow recruitment (105 patients over 2,5 years), lack of funding, need for more centers, and the changing treatment landscape (approval of ICIs in combination with other cancer treatments).”Registry text, quoted unchanged. Source
Trials that share participant data
Trials whose registry record says individual participant data (IPD) will be shared.
Study to Evaluate the Efficacy of Immunosuppression in Myocarditis or Inflammatory Cardiomyopathy.
AbataCept for the Treatment of Immune-cHeckpoint Inhibitors Induced mYocarditiS
Genetic Determinants of Myocarditis Induced by Immune-checkpoint Inhibitors
Pulse Corticosteroids Or/and Immunoglobulins to Treat Fulminant Myocarditis
Search by method
Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.
- Single-Cell Analysis 8
- Organoids 1
- Mendelian Randomization Analysis 5
- Gene Expression Profiling 12
- Sequence Analysis, RNA 1
- Whole Genome Sequencing 1
- Exome Sequencing 2
- Proteomics 8
- Metabolomics 4
- Flow Cytometry 3
- Immunohistochemistry 8
- Positron-Emission Tomography 11
- Magnetic Resonance Imaging 60
- Machine Learning 5
- Deep Learning 3
- Cohort Studies 16
- Genome-Wide Association Study 5
Paste an abstract
See which targets of this disease your abstract mentions, and go to the people working on them.
Matched in your browser only. The text is not sent, saved or logged.
Sources: ClinicalTrials.gov, EU CTR, OpenAlex, PubMed. Machine-matched links are labelled.